
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen is poised for significant growth with its Papzimeos launch momentum, providing a solid foundation for being designated as an HCW 2H26 Top Pick. With projected sales of $27M in 2Q26 and $130M in 2026, the company is well-positioned for cash flow break-even by the end of 2026. In addition, the upcoming ASCO data and label expansion opportunities could further drive adoption of Papzimeos and showcase the potential of Precigen's AdenoVerse pipeline.
Bears say
Precigen is expected to have a negative outlook due to Inovio's significant competition in the RRP market, with their immunotherapy INO-3107 targeting HPV-6 and HPV-11. The FDA's concerns regarding Inovio's accelerated approval for their BLA may also hinder Precigen's market exclusivity and peak penetration, leading to conservative estimates for US sales to only reach $1B in 2033.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares